Stifel Nicolaus Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR)

Investment analysts at Stifel Nicolaus started coverage on shares of Kymera Therapeutics (NASDAQ:KYMR) in a report released on Tuesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $55.00 price target on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 82.54% from the stock’s previous close.

A number of other analysts have also recently weighed in on KYMR. HC Wainwright raised their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. UBS Group lowered their price objective on Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, May 13th. Citigroup started coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They issued a “buy” rating and a $52.00 price objective for the company. Bank of America lowered their price objective on Kymera Therapeutics from $47.00 to $44.00 and set a “neutral” rating for the company in a research report on Monday, May 12th. Finally, Guggenheim reissued a “buy” rating and issued a $52.00 price objective on shares of Kymera Therapeutics in a research report on Monday, May 12th. Four analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Kymera Therapeutics has an average rating of “Moderate Buy” and an average target price of $55.25.

Kymera Therapeutics Trading Down 4.2%

Shares of NASDAQ KYMR opened at $30.13 on Tuesday. The stock has a market capitalization of $1.96 billion, a PE ratio of -12.88 and a beta of 2.18. The stock’s fifty day simple moving average is $29.14 and its two-hundred day simple moving average is $36.72. Kymera Therapeutics has a 12-month low of $19.45 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.10. The business had revenue of $22.10 million for the quarter, compared to analysts’ expectations of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business’s revenue for the quarter was up 114.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.69) EPS. On average, equities analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares in the company, valued at approximately $6,147,428.70. This trade represents a 3.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the transaction, the chief operating officer now owns 67,800 shares of the company’s stock, valued at $2,064,510. The trade was a 2.00% decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,659 shares of company stock worth $324,567 in the last 90 days. Insiders own 16.01% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Blue Trust Inc. raised its stake in shares of Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after buying an additional 270 shares during the last quarter. KBC Group NV raised its stake in shares of Kymera Therapeutics by 15.2% during the 1st quarter. KBC Group NV now owns 2,479 shares of the company’s stock valued at $68,000 after buying an additional 328 shares during the last quarter. Summit Investment Advisors Inc. grew its position in shares of Kymera Therapeutics by 9.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company’s stock valued at $198,000 after acquiring an additional 406 shares during the period. Comerica Bank grew its position in shares of Kymera Therapeutics by 3.6% during the 1st quarter. Comerica Bank now owns 21,374 shares of the company’s stock valued at $585,000 after acquiring an additional 743 shares during the period. Finally, Hsbc Holdings PLC grew its position in shares of Kymera Therapeutics by 6.1% during the 1st quarter. Hsbc Holdings PLC now owns 18,547 shares of the company’s stock valued at $508,000 after acquiring an additional 1,064 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.